According to a Consumer Reports blog entry, the recent historic $3 billion settlement against pharmaceutical giant GlaxoSmithKline carries some important lessons for consumers.
Prescribing a drug “off-label,” or for a purpose different from the use specified in its U.S. Food and Drug Administration approval, is legal. But promoting a drug for off-label use is not.
And apparently GSK did exactly that, through tactics that included misrepresenting research data to show benefits and ...
continue reading...